PuSH - Publication Server of Helmholtz Zentrum München

Koch, M. ; de Jong, J.S.* ; Glatz, J. ; Symvoulidis, P. ; Lamberts, L.E.* ; Adams, A.L.L.* ; Kranendonk, M.E.G.* ; van Scheltinga, A.T.* ; Aichler, M. ; Jansen, L.* ; de Vries, J.* ; Lub-de Hooge, M.* ; Schröder, C.P.* ; Jorritsma-Smit, A.* ; Linssen, M.D.* ; de Boer, E.* ; van der Vegt, B.* ; Nagengast, W.B.* ; Elias, S.G.* ; Oliveira, S.* ; Witkamp, A.J.* ; Mali, W.P.Th.M.* ; van der Wall, E.* ; Garcia-Allende, P. ; van Diest, P.J.* ; de Vries, E.G.* ; Walch, A.K. ; van Dam, G.M.* ; Ntziachristos, V.

Fluorescently labeled bevacizumab in human breast cancer: Defining the classification threshold.

Proc. SPIE 10411:104110F (2017)
Publ. Version/Full Text DOI
Open Access Green as soon as Postprint is submitted to ZB.
In-vivo fluorescently labelled drug (bevacizumab) breast cancer specimen where obtained from patients. We propose a new structured method to determine the optimal classification threshold in targeted fluorescence intra-operative imaging.
Impact Factor
Scopus SNIP
Altmetric
0.000
0.384
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Imaging systems, Medical and biological imaging, Clinical applications
Language english
Publication Year 2017
HGF-reported in Year 2017
ISSN (print) / ISBN 0277-786X
e-ISSN 1996-756X
Conference Title European Conferences on Biomedical Optics
Conference Date 25-29 June 2017
Conference Location Munich, Germany
Quellenangaben Volume: 10411, Issue: , Pages: , Article Number: 104110F Supplement: ,
Publisher SPIE
Reviewing status Peer reviewed
POF-Topic(s) 30205 - Bioengineering and Digital Health
Research field(s) Enabling and Novel Technologies
PSP Element(s) G-505500-001
G-500390-001
Scopus ID 85033566002
Scopus ID 85032258866
Erfassungsdatum 2017-09-06